AMCR Stock Analysis: Amcor | NYSE
Packaging & Containers | NYSE, USA | Market Cap: 19.309m USD | 12M Return: 10.9% | JE00BV7DQ550 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 136M
EPS Trend: -70.6%
Qual. Beats: 1
Rev. Trend: 82.5%
Qual. Beats: 2
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Amcor plc is a global packaging manufacturer headquartered in Zurich, Switzerland, that develops and produces packaging solutions primarily for the nutrition, health, beauty, and wellness categories across Europe, North America, Latin America, and the Asia Pacific. The company operates through two main segments: Global Flexible Packaging Solutions, which supplies polymer resin, aluminum, and fiber-based flexible packaging, and Global Rigid Packaging Solutions, which manufactures rigid containers, closures, and dispensing and pharma delivery devices. Its product portfolio spans bottles, vials, jars, films, laminates, tubes, trays, lids, tapes, and wipes packaging, among other items, sold through a direct sales force.
Founded in 1926 and listed on the NYSE in 2019, Amcor is classified within the Materials sector under the Metal, Glass & Plastic Containers sub-industry. Packaging companies in this segment typically generate revenue through high-volume, contract-based supply relationships with consumer goods manufacturers, with demand tied to underlying trends in packaged food, beverage, pharmaceutical, and personal care consumption worldwide.
- Berry Global merger closes, expanding global packaging scale
- Resin and aluminum cost volatility pressures packaging margins
- Healthcare rigid packaging segment grows on pharma demand
| Net Income: 1.11b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 1.30 > 1.0 |
| NWC/Revenue: 8.04% < 20% (prev 9.64%; Δ -1.60% < -1%) |
| CFO/TA 0.06 > 3% & CFO 2.23b > Net Income 1.11b |
| Net Debt (14.8b) to EBITDA (3.52b): 4.21 < 3 |
| Current Ratio: 1.25 > 1.5 & < 3 |
| Outstanding Shares: last quarter (463.8m) vs 12m ago 45.57% < -2% |
| Gross Margin: 19.23% > 18% (prev 18.88%; Δ 0.35% > 0.5%) |
| Asset Turnover: 63.39% > 50% (prev 40.49%; Δ 22.90% > 0%) |
| Interest Coverage Ratio: 3.37 > 6 (EBIT TTM 2.04b / Interest Expense TTM 606.0m) |
| A: 0.05 (Total Current Assets 9.33b - Total Current Liabilities 7.43b) / Total Assets 37.1b |
| B: 0.01 (Retained Earnings 459.0m / Total Assets 37.1b) |
| C: 0.06 (EBIT TTM 2.04b / Avg Total Assets 37.1b) |
| D: 0.47 (Book Value of Equity 11.8b / Total Liabilities 25.3b) |
| Altman-Z'' = 1.23 = BB |
| DSRI: 0.68 (Receivables 3.64b/3.43b, Revenue 23.5b/15.0b) |
| GMI: 0.98 (GM 18.88% / 19.23%) |
| AQI: 1.00 (AQ_t 0.52 / AQ_t-1 0.52) |
| SGI: 1.57 (Revenue 23.5b / 15.0b) |
| TATA: -0.03 (NI 1.11b - CFO 2.23b) / TA 37.1b) |
| Beneish M = -2.90 (Cap -4..+1) = A |
As of October 12, 2026, the stock is trading at USD 41.72 with a total of 2,716,155 shares traded. Over the past week, the price has changed by -0.33%, over one month by -1.42%, over three months by -0.26% and over the past year by +10.92%.
Current recommended Stop Loss: 40.50 (which is 2.9% or 1.3 ATR below the current price).
Amcor has received a consensus analysts rating of 3.93. Therefore, it is recommended to buy AMCR.
- StrongBuy: 6
- Buy: 1
- Hold: 7
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 50.2 | 20.3% |
P/E Trailing = 17.563
P/E Forward = 10.582
P/S = 0.8215
P/B = 1.6784
P/EG = 0.9797
Revenue TTM = 23.5b USD
EBIT TTM = 2.04b USD
EBITDA TTM = 3.52b USD
Long Term Debt = 13.9b USD (from longTermDebt, last quarter)
Short Term Debt = 366.0m USD (from shortTermDebt, last quarter)
Debt = 15.9b USD (from shortLongTermDebtTotal, last quarter) + Leases 852.0m
Net Debt = 14.8b USD (calculated: Debt 15.9b - CCE 1.11b)
Enterprise Value = 34.1b USD (19.3b + Debt 15.9b - CCE 1.11b)
Interest Coverage Ratio = 3.37 (Ebit TTM 2.04b / Interest Expense TTM 606.0m)
EV/FCF = 26.41x (Enterprise Value 34.1b / FCF TTM 1.29b)
FCF Yield = 3.79% (FCF TTM 1.29b / Enterprise Value 34.1b)
FCF Margin = 5.50% (FCF TTM 1.29b / Revenue TTM 23.5b)
Net Margin = 4.71% (Net Income TTM 1.11b / Revenue TTM 23.5b)
Gross Margin = 19.23% ((Revenue TTM 23.5b - Cost of Revenue TTM 19.0b) / Revenue TTM)
Gross Margin QoQ = 25.24% (prev 20.12%)
Tobins Q-Ratio = 0.92 (Enterprise Value 34.1b / Total Assets 37.1b)
Interest Expense / Debt = 3.80% (Interest Expense 606.0m / Debt 15.9b)
Taxrate = 12.82% (181.0m / 1.41b)
NOPAT = 1.78b (EBIT 2.04b * (1 - 12.82%))
Current Ratio = 1.25 (Total Current Assets 9.33b / Total Current Liabilities 7.43b)
Debt / Equity = 1.35 (Debt 15.9b / totalStockholderEquity, last quarter 11.8b)
Debt / EBITDA = 4.21 (Net Debt 14.8b / EBITDA 3.52b)
Debt / FCF = 11.47 (Net Debt 14.8b / FCF TTM 1.29b)
Total Stockholder Equity = 11.7b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.98% (Net Income 1.11b / Total Assets 37.1b)
RoE = 9.45% (Net Income TTM 1.11b / Total Stockholder Equity 11.7b)
RoCE = 7.98% (EBIT 2.04b / Capital Employed (Equity 11.7b + L.T.Debt 13.9b))
RoIC = 6.15% (NOPAT 1.78b / Invested Capital 28.9b)
WACC = 5.71% (E(19.3b)/V(35.2b) * Re(7.68%) + D(15.9b)/V(35.2b) * Rd(3.80%) * (1-Tc(0.13)))
Discount Rate = 7.68% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 88.07 | Cagr: 23.59%
[DCF] Terminal Value 77.97% ; FCFF base≈1.10b ; Y1≈1.26b ; Y5≈1.85b
[DCF] Fair Price = 28.34 (EV 27.9b - Net Debt 14.8b = Equity 13.1b / Shares 461.9m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -70.56 | EPS CAGR: -6.17% | SUE: 1.16 | # QB: 1
Revenue Correlation: 82.46 | Revenue CAGR: 20.75% | SUE: 3.75 | # QB: 2
EPS current Quarter (2026-09-30): EPS=0.99 | Chg30d=-5.69% | Revisions=+0% | Analysts=4
EPS current Year (2026-12-31): EPS=4.04 | Chg30d=+0.09% | Revisions=+0% | GrowthEPS=+13.4% | GrowthRev=+59.1%
EPS next Year (2027-06-30): EPS=4.28 | Chg30d=-0.23% | Revisions=-50% | GrowthEPS=+6.4% | GrowthRev=+1.0%
[Analyst] Revisions Ratio: -50% (up=0, down=3)